At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
Glucagon-only Bionic Pancreasdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Closed-Loop Glucagon Administration for the Automated Prevention and Treatment of Hypoglycemia
In Brief
A clinical study evaluating Glucagon-only Bionic Pancreas for Type 1 Diabetes. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes \> 21 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsBoston University
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartNov 2014
Primary CompletionJun 2015
Study CompletionApr 2017
TodayJul 2026
First PostedJul 3, 2014
Enrollment StartNov 1, 2014
Primary CompletionJun 1, 2015
Study CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.0 years ago
Interventions
Glucagon-only Bionic Pancreasdevice
A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.